Table 3 Pathologic characteristics from the eligible studies
From: Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis
Study | Tumor grade (G0/G1/G2/G3) | Pathologic T stage (pT0/is/a/1/2/3/4) | Pathologic N stage (pN1/2/3) | Median no. of LNs removed, range | Median no. of positive LNs, range | Median LN density, range (%) |
|---|---|---|---|---|---|---|
Herr [5] | NA | 79 (≤T2)/123/0 | 54/87/21 | 13 (2–32) | 3.3 | NA |
Fleischmann [18] | NA | 0/0/0/19 (T1/2)/53/30 | 32/69/0 | 22 (10–43) | NA | NA |
Osawa [19] | 0/0/9/51 | 0/0/0/1/6/38/15 | 21/39 | 12 (1–80) | 2 (1–12) | 23.1 (1.3-100) |
Wiesner [20] | 0/0/8/38 | 0/0/0/3/11/24/8 | NA | 33 (15–77) | 3 (1–28) | 11 (1–73) |
Furukawa [21] | 0/0/12/70 | 0/0/0/0/19/37/26 | 32/50/0 | 14.4 (mean) (6–37) | 3.1 (mean) (1–12) | 25.3 (2.8–100) |
Guzzo [22] | NA | 9 (≤T1)/13/63 (T3/4) | NA | 16.7 (mean) (5–56) | NA | NA |
Stephenson [23] | NA | 107 (≤T2)/27 (T3/4) | 62/72 (N2/3) | 14 (IQR: 9–20) | 2 (IQR: 1–3) | 17 (IQR: 9–38) |
May [24] | 79 (≤G2)/398 | 24 (≤T1)/103/350 (T3/4) | 187/290/0 | 12 (1–66) | 2 (1–25) | 17.6 (2.3–100) |
Jensen [25] | NA | NA | 16/9/18 | NA | NA | NA |
Morgan [26] | 27 (LG)/741 (HG) | 14 (≤T1)/48/131/585 | NA | 9 (IQR: 4–16) | 2 (IQR: 1–3) | 25 (IQR: 13–50) |
Kassouf [27] | NA | 65 (≤T1)/176/505/292 | NA | 18 (IQR: 11–32) | 2 (IQR: 1–5) | 14.3 (IQR: 6.7–33.3) |
Masson-Lecomte [28] | NA | 0/0/0/2/15/39/19 | 10/10/6 | 18 (3–49) | 3 (1–35) | 19 (2–100) |
Mmeje [29] | NA | 0/1/0/2/13/26/7 | NA | 19 (mean) (5–35) | 3 (mean) (1–12) | NA |
Kwon [30] | NA | NA | 62/116/1 | 16 (1–118) | 3 (1–37) | 17.6 (2.6–100) |